An Automatic Learning Platform To Annotate Variants of Unknown Significance
Santiago Demajo
Breaking Science Videos
Renowned experts in oncology share their knowledge in our ESMO Breaking Science Video Series
Data from First Interim Analysis of the Comprehensive Clinico-Genomics Database Network in Germany
Maike Collienne
MTB Offers Matched Therapies Beyond ESCAT Tier 1 Alterations in Patients with Advanced Cancer
Victor Segui-Manzaneque
Multiple Instance Learning Applied to Digital Pathology for Prediction of BRCA Mutations in Prostate Cancer
Carlos Macarro
Pre-Clinical Pan-Cancer Drug Repurposing via Deep Learning
Beronica A. Ocasio
Tackling Heterogeneity of Endocrine Resistance in ER-positive Breast Cancer
Anton Patrikeev
Neoadjuvant Nivolumab Plus Relatlimab in MMR-deficient Colon Cancer
Peter G. de Gooyer
Neoadjuvant Pembrolizumab in Cohort of Patients with dMMR/MSI Colorectal Cancer
Christelle De la Fouchardiere
Pembrolizumab in Combination with CAPOX and Bevacizumab in Patients with MSS mCRC and a High Immune Infiltrate
David Tougeron
Sotorasib, Panitumumab and FOLFIRI in the First-Line Setting for KRAS G12C–mutated mCRC
Salvatore Siena
Trastuzumab deruxtecan monotherapy and combinations in patients with advanced/metastatic HER2-positive (HER2+) G/GEJ adenocarcinoma
Yelena Y. Janjigian
Breastfeeding After Breast Cancer in Young BRCA Carriers
Eva Blondeaux
Effects of High-Intensity Exercise on Breast Cancer Recurrence and Survival
Helene Rundqvist
Stereotactic body radiation therapy+/- durvalumab +/- oleclumab combined with neo-adjuvant chemotherapy for early-stage, high risk ER+/HER2 - breast cancer
Alex De Caluwe
First-Line Carboplatin-Cyclophosphamide versus Paclitaxel With or Without Atezolizumab for metastatic TNBC
Marleen Kok
Patritumab Deruxtecan in Patients with HR+/HER2- Advanced Breast Cancer
Barbara Pistilli
OS: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
Domenica Lorusso
Cabozantinib versus Placebo for Advanced Neuroendocrine Tumours After Progression on Prior Therapy
Jennifer Chan
Multivariable Analysis of Streptozotocin plus 5-Fluorouracil and Everolimus Sequences in Advanced Pancreatic Neuroendocrine Tumors
Ramon Salazar Soler
Eftilagimod Alpha (Soluble LAG-3) Plus Pembrolizumab versus Pembrolizumab in First-Line Recurrent or Metastatic HNSCC with CPS ≥1
Claus Andrup Kristensen
Trastuzumab Deruxtecan in Patients with HER2-positive Recurrent/Metastatic Salivary Gland Cancer
Ichiro Kinoshita
Regorafenib as Maintenance Therapy after First-Line Doxorubicin-based Chemotherapy in Advanced Soft Tissue Sarcoma
Nicolas Penel
Vimseltinib for Patients with Tenosynovial Giant Cell Tumour
Hans Gelderblom
DMFS: Neoadjuvant Nivolumab Plus Ipilimumab versus Adjuvant Nivolumab in Resectable, Macroscopic Stage III Melanoma
Minke W. Lucas
Haloperidol and Lorazepam for Agitated Delirium in Patients with Advanced Cancer
David Hui
Ponsegromab for Patients with Cancer Cachexia
Jeffrey Crawford
NVL-655 in Patients with ALK-Positive Solid Tumours
Alexander E. Drilon
Outcomes of Durvalumab as Consolidation Treatment in Limited-Stage SCLC
Suresh Senan
Antibody-drug conjugates efficacy and safety in metastatic breast cancer
Komal Jhaveri
Capivasertib and fulvestrant for AI-resistant HR+/HER2- ABC
Hope Rugo
Atezolizumab and sacituzumab govitecan for advanced TNBC
Peter Schmid
ESR1m ctDNA in MBC patients treated by camizestrant
Mafalda Oliveira
Safety of assisted fertility after breast cancer in young BRCA carriers
Matteo Lambertini
Triple combination therapy for ER+ / HER2- ABC with HRR deficiency or MSI
Séverine Guiu
HER2DX assay and survival outcomes
Guillermo Villacampa